#ID(s) interactor A	ID(s) interactor B	Alt. ID(s) interactor A	Alt. ID(s) interactor B	Alias(es) interactor A	Alias(es) interactor B	Interaction detection method(s)	Publication 1st author(s)	Publication Identifier(s)	Taxid interactor A	Taxid interactor B	Interaction type(s)	Source database(s)	Interaction identifier(s)	Confidence value(s)	Expansion method(s)	Biological role(s) interactor A	Biological role(s) interactor B	Experimental role(s) interactor A	Experimental role(s) interactor B	Type(s) interactor A	Type(s) interactor B	Xref(s) interactor A	Xref(s) interactor B	Interaction Xref(s)	Annotation(s) interactor A	Annotation(s) interactor B	Interaction annotation(s)	Host organism(s)	Interaction parameter(s)	Creation date	Update date	Checksum(s) interactor A	Checksum(s) interactor B	Interaction Checksum(s)	Negative	Feature(s) interactor A	Feature(s) interactor B	Stoichiometry(s) interactor A	Stoichiometry(s) interactor B	Identification method participant A	Identification method participant B
uniprotkb:P00521	uniprotkb:O75896	intact:EBI-1550592	intact:EBI-1052725|uniprotkb:B2R4Y9|ensembl:ENSP00000232496	psi-mi:abl_mlvab(display_long)|uniprotkb:ABL(gene name)|psi-mi:ABL(display_short)|uniprotkb:V-abl(gene name synonym)	psi-mi:tusc2_human(display_long)|uniprotkb:PDGFA-associated protein 2(gene name synonym)|uniprotkb:Fusion 1 protein(gene name synonym)|uniprotkb:TUSC2(gene name)|psi-mi:TUSC2(display_short)|uniprotkb:FUS1(gene name synonym)|uniprotkb:LGCC(gene name synonym)|uniprotkb:PDAP2(gene name synonym)|uniprotkb:C3orf11(gene name synonym)	psi-mi:"MI:0424"(protein kinase assay)	Lin et al. (2007)	imex:IM-14938|pubmed:17486070	taxid:11788(mlvab)|taxid:11788(Abelson murine leukemia virus)	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0414"(enzymatic reaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-1550612|imex:IM-14938-1	-	-	psi-mi:"MI:0501"(enzyme)	psi-mi:"MI:0586"(inhibitor)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0326"(protein)	psi-mi:"MI:0326"(protein)	interpro:IPR033221|interpro:IPR015015(F-actin binding)|interpro:IPR011009(Protein kinase-like)|interpro:IPR000719(Protein kinase, core)|interpro:IPR017441(Protein kinase ATP binding, conserved site)|interpro:IPR001245(Tyrosine protein kinase)|interpro:IPR000980(SH2 motif)|interpro:IPR008266(Tyrosine protein kinase, active site)|interpro:IPR020635|interpro:IPR035837|interpro:IPR036860|go:"GO:0004714"(transmembrane receptor protein tyrosine kinase activity)|go:"GO:0004715"(non-membrane spanning protein tyrosine kinase activity)|go:"GO:0005524"(ATP binding)	refseq:NP_009206.1|ensembl:ENSG00000114383(gene)|ensembl:ENST00000232496(transcript)|go:"GO:0001779"(natural killer cell differentiation)|go:"GO:0005739"(mitochondrion)|go:"GO:0006909"(phagocytosis)|go:"GO:0006954"(inflammatory response)|go:"GO:0007049"(cell cycle)|go:"GO:0032700"(negative regulation of interleukin-17 production)|go:"GO:0032733"(positive regulation of interleukin-10 production)|go:"GO:0048469"(cell maturation)|go:"GO:0051881"(regulation of mitochondrial membrane potential)|go:"GO:0070945"(neutrophil-mediated killing of gram-negative bacterium)|go:"GO:2000377"(regulation of reactive oxygen species metabolic process)|interpro:IPR029393	psi-mi:"MI:0469"(intact)	-	-	figure legend:1 A|comment:The substrate of Abl kinase in this assay is GST-CRK.|comment:The Fus1 peptide was modified with a stearate N-terminal moiety. The Fus1 peptide lacking the stearate N-terminal moiety did not inhibit Abl kinase activity.|inhibition:Stearate-Fus1 peptide - The peptide inhibits Abl activity and inhibition increases as the concentration of peptide is increased.|kinetics:IC50 = 3.5 E-5 M|dataset:Apoptosis - Interactions involving proteins with a function related to apoptosis|dataset:Cancer - Interactions investigated in the context of cancer|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2007/10/30	2014/10/16	rogid:LQlWvc7h3MgjSCvV5WP1v0kjBwA11788	rogid:mNKu48f2Yc8KQdyQ8gQXjfTnD1c9606	intact-crc:ECA480F058DE4FF1|rigid:u+qgos2qCFuamxbxGh5PkuiXoeE	false	sufficient binding region:13..13-379..379	lipoconjugated residue:n-n|sufficient binding region:75-97	-	-	psi-mi:"MI:0396"(predetermined participant)	psi-mi:"MI:0396"(predetermined participant)
intact:EBI-3946155	uniprotkb:P00519	-	intact:EBI-375543|uniprotkb:Q13869|uniprotkb:Q13870|uniprotkb:Q16133|uniprotkb:Q45F09|ensembl:ENSP00000323315|uniprotkb:A3KFJ3|uniprotkb:Q17R61|intact:EBI-1550796	psi-mi:abl-tide(display_short)|psi-mi:EBI-3946155(display_long)	psi-mi:abl1_human(display_long)|uniprotkb:Abelson tyrosine-protein kinase 1(gene name synonym)|uniprotkb:ABL1(gene name)|psi-mi:ABL1(display_short)|uniprotkb:ABL(gene name synonym)|uniprotkb:JTK7(gene name synonym)|uniprotkb:Abelson murine leukemia viral oncogene homolog 1(gene name synonym)|uniprotkb:Proto-oncogene c-Abl(gene name synonym)|uniprotkb:p150(gene name synonym)	psi-mi:"MI:0424"(protein kinase assay)	Lin et al. (2007)	imex:IM-14938|pubmed:17486070	taxid:-2(chemical synthesis)|taxid:-2("Chemical synthesis (Chemical synthesis)")	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0414"(enzymatic reaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-1550813|imex:IM-14938-2	-	psi-mi:"MI:1060"(spoke expansion)	psi-mi:"MI:0502"(enzyme target)	psi-mi:"MI:0501"(enzyme)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0503"(self)	psi-mi:"MI:0327"(peptide)	psi-mi:"MI:0326"(protein)	-	refseq:NP_005148.2|refseq:NP_009297.2|ensembl:ENSG00000097007(gene)|ensembl:ENST00000318560(transcript)|go:"GO:0000278"(mitotic cell cycle)|go:"GO:0000287"(magnesium ion binding)|go:"GO:0000400"(four-way junction DNA binding)|go:"GO:0000405"(bubble DNA binding)|go:"GO:0006897"(endocytosis)|go:"GO:0006914"(autophagy)|go:"GO:0006974"(cellular response to DNA damage stimulus)|go:"GO:0006975"(DNA damage induced protein phosphorylation)|go:"GO:0006979"(response to oxidative stress)|go:"GO:0007173"(epidermal growth factor receptor signaling pathway)|go:"GO:0007204"(positive regulation of cytosolic calcium ion concentration)|go:"GO:0007229"(integrin-mediated signaling pathway)|go:"GO:0008022"(protein C-terminus binding)|go:"GO:0008630"(intrinsic apoptotic signaling pathway in response to DNA damage)|go:"GO:0009791"(post-embryonic development)|go:"GO:0010506"(regulation of autophagy)|go:"GO:0010595"(positive regulation of endothelial cell migration)|go:"GO:0015629"(actin cytoskeleton)|go:"GO:0016301"(kinase activity)|go:"GO:0016604"(nuclear body)|go:"GO:0017124"(SH3 domain binding)|go:"GO:0018108"(peptidyl-tyrosine phosphorylation)|go:"GO:0019905"(syntaxin binding)|go:"GO:0021587"(cerebellum morphogenesis)|go:"GO:0022408"(negative regulation of cell-cell adhesion)|go:"GO:0030035"(microspike assembly)|go:"GO:0030036"(actin cytoskeleton organization)|go:"GO:0030100"(regulation of endocytosis)|go:"GO:0030145"(manganese ion binding)|go:"GO:0030155"(regulation of cell adhesion)|go:"GO:0001784"(phosphotyrosine residue binding)|go:"GO:0001843"(neural tube closure)|go:"GO:0001922"(B-1 B cell homeostasis)|go:"GO:0001934"(positive regulation of protein phosphorylation)|go:"GO:0002322"(B cell proliferation involved in immune response)|go:"GO:0002333"(transitional one stage B cell differentiation)|go:"GO:0003677"(DNA binding)|go:"GO:0003713"(transcription coactivator activity)|go:"GO:0003785"(actin monomer binding)|go:"GO:0004515"(nicotinate-nucleotide adenylyltransferase activity)|go:"GO:0004672"(protein kinase activity)|go:"GO:0004713"(protein tyrosine kinase activity)|go:"GO:0004714"(transmembrane receptor protein tyrosine kinase activity)|go:"GO:0004715"(non-membrane spanning protein tyrosine kinase activity)|go:"GO:0005080"(protein kinase C binding)|go:"GO:0005524"(ATP binding)|go:"GO:0005634"(nucleus)|go:"GO:0005654"(nucleoplasm)|go:"GO:0005730"(nucleolus)|go:"GO:0005737"(cytoplasm)|go:"GO:0005739"(mitochondrion)|go:"GO:0005829"(cytosol)|go:"GO:0006298"(mismatch repair)|go:"GO:0006355"(regulation of transcription, DNA-templated)|go:"GO:0006464"(cellular protein modification process)|go:"GO:0006468"(protein phosphorylation)|go:"GO:0030425"(dendrite)|go:"GO:0030514"(negative regulation of BMP signaling pathway)|go:"GO:0030516"(regulation of axon extension)|go:"GO:0031113"(regulation of microtubule polymerization)|go:"GO:0031252"(cell leading edge)|go:"GO:0031965"(nuclear membrane)|go:"GO:0032489"(regulation of Cdc42 protein signal transduction)|go:"GO:0032729"(positive regulation of interferon-gamma production)|go:"GO:0032743"(positive regulation of interleukin-2 production)|go:"GO:0032956"(regulation of actin cytoskeleton organization)|go:"GO:0032991"(protein-containing complex)|go:"GO:0033690"(positive regulation of osteoblast proliferation)|go:"GO:0034446"(substrate adhesion-dependent cell spreading)|go:"GO:0034599"(cellular response to oxidative stress)|go:"GO:0035791"(platelet-derived growth factor receptor-beta signaling pathway)|go:"GO:0038083"(peptidyl-tyrosine autophosphorylation)|go:"GO:0038096"(Fc-gamma receptor signaling pathway involved in phagocytosis)|go:"GO:0038189"(neuropilin signaling pathway)|go:"GO:0038191"(neuropilin binding)|go:"GO:0042169"(SH2 domain binding)|go:"GO:0042770"(signal transduction in response to DNA damage)|go:"GO:0042981"(regulation of apoptotic process)|go:"GO:0043025"(neuronal cell body)|go:"GO:0043065"(positive regulation of apoptotic process)|go:"GO:0043123"(positive regulation of I-kappaB kinase/NF-kappaB signaling)|go:"GO:0043124"(negative regulation of I-kappaB kinase/NF-kappaB signaling)|go:"GO:0043542"(endothelial cell migration)|go:"GO:0045184"(establishment of protein localization)|go:"GO:0045580"(regulation of T cell differentiation)|go:"GO:0045930"(negative regulation of mitotic cell cycle)|go:"GO:0045931"(positive regulation of mitotic cell cycle)|go:"GO:0045944"(positive regulation of transcription by RNA polymerase II)|go:"GO:0046632"(alpha-beta T cell differentiation)|go:"GO:0046777"(protein autophosphorylation)|go:"GO:0046875"(ephrin receptor binding)|go:"GO:0048471"(perinuclear region of cytoplasm)|go:"GO:0048536"(spleen development)|go:"GO:0048538"(thymus development)|go:"GO:0048668"(collateral sprouting)|go:"GO:0050731"(positive regulation of peptidyl-tyrosine phosphorylation)|go:"GO:0050798"(activated T cell proliferation)|go:"GO:0050852"(T cell receptor signaling pathway)|go:"GO:0050853"(B cell receptor signaling pathway)|go:"GO:0050885"(neuromuscular process controlling balance)|go:"GO:0051015"(actin filament binding)|go:"GO:0051019"(mitogen-activated protein kinase binding)|go:"GO:0051281"(positive regulation of release of sequestered calcium ion into cytosol)|go:"GO:0051353"(positive regulation of oxidoreductase activity)|go:"GO:0051444"(negative regulation of ubiquitin-protein transferase activity)|go:"GO:0051496"(positive regulation of stress fiber assembly)|go:"GO:0051726"(regulation of cell cycle)|go:"GO:0051882"(mitochondrial depolarization)|go:"GO:0051894"(positive regulation of focal adhesion assembly)|go:"GO:0060020"(Bergmann glial cell differentiation)|go:"GO:0060563"(neuroepithelial cell differentiation)|go:"GO:0070064"(proline-rich region binding)|go:"GO:0070301"(cellular response to hydrogen peroxide)|go:"GO:0070373"(negative regulation of ERK1 and ERK2 cascade)|go:"GO:0070374"(positive regulation of ERK1 and ERK2 cascade)|go:"GO:0071103"(DNA conformation change)|go:"GO:0071222"(cellular response to lipopolysaccharide)|go:"GO:0071901"(negative regulation of protein serine/threonine kinase activity)|go:"GO:0072359"(circulatory system development)|go:"GO:0090050"(positive regulation of cell migration involved in sprouting angiogenesis)|go:"GO:0090135"(actin filament branching)|go:"GO:0098794"(postsynapse)|go:"GO:1900026"(positive regulation of substrate adhesion-dependent cell spreading)|go:"GO:1900272"(negative regulation of long-term synaptic potentiation)|go:"GO:1900275"(negative regulation of phospholipase C activity)|go:"GO:1901216"(positive regulation of neuron death)|go:"GO:1902036"(regulation of hematopoietic stem cell differentiation)|go:"GO:1903053"(regulation of extracellular matrix organization)|go:"GO:1903351"(cellular response to dopamine)|go:"GO:1904528"(positive regulation of microtubule binding)|go:"GO:1904531"(positive regulation of actin filament binding)|go:"GO:1905244"(regulation of modification of synaptic structure)|go:"GO:1905555"(positive regulation of blood vessel branching)|go:"GO:1990051"(activation of protein kinase C activity)|go:"GO:1990837"(sequence-specific double-stranded DNA binding)|go:"GO:2000096"(positive regulation of Wnt signaling pathway, planar cell polarity pathway)|go:"GO:2000145"(regulation of cell motility)|go:"GO:2000249"(regulation of actin cytoskeleton reorganization)|go:"GO:2000251"(positive regulation of actin cytoskeleton reorganization)|go:"GO:2000352"(negative regulation of endothelial cell apoptotic process)|go:"GO:2000773"(negative regulation of cellular senescence)|go:"GO:2001020"(regulation of response to DNA damage stimulus)|interpro:IPR000719(Protein kinase, core)|interpro:IPR000980(SH2 motif)|interpro:IPR001245(Tyrosine protein kinase)|interpro:IPR001452(Src homology-3)|interpro:IPR008266(Tyrosine protein kinase, active site)|interpro:IPR011009(Protein kinase-like)|interpro:IPR015015(F-actin binding)|interpro:IPR017441(Protein kinase ATP binding, conserved site)|interpro:IPR020635|interpro:IPR033221|interpro:IPR035837|interpro:IPR036028|interpro:IPR036860|mint:P00519|rcsb pdb:1AB2|rcsb pdb:1ABL|rcsb pdb:2HIW|rcsb pdb:2HYY|rcsb pdb:2HZ0|rcsb pdb:2HZ4|rcsb pdb:2HZI|rcsb pdb:2O88|rcsb pdb:2V7A|rcsb pdb:3CS9|rcsb pdb:3EG0|rcsb pdb:3EG1|rcsb pdb:3EG2|rcsb pdb:3EG3|rcsb pdb:3EGU|rcsb pdb:3K2M|rcsb pdb:3PYY|rcsb pdb:3QRI|rcsb pdb:3QRJ|rcsb pdb:3QRK|rcsb pdb:3T04|rcsb pdb:3UE4|rcsb pdb:3UYO|rcsb pdb:4J9B|rcsb pdb:4J9C|rcsb pdb:4J9D|rcsb pdb:1AWO|rcsb pdb:1BBZ|rcsb pdb:1JU5|rcsb pdb:1OPL|rcsb pdb:1ZZP|rcsb pdb:2ABL|rcsb pdb:2E2B|rcsb pdb:2F4J|rcsb pdb:2FO0|rcsb pdb:4J9E|rcsb pdb:2G1T|rcsb pdb:4J9F|rcsb pdb:2G2F|rcsb pdb:2G2H|rcsb pdb:4J9G|rcsb pdb:2G2I|rcsb pdb:4J9H|rcsb pdb:2GQG|rcsb pdb:4J9I|rcsb pdb:4JJB|rcsb pdb:4JJC|rcsb pdb:4JJD|rcsb pdb:4TWP|rcsb pdb:4WA9|rcsb pdb:4XEY|rcsb pdb:4YC8|rcsb pdb:4ZOG|rcsb pdb:5DC0|rcsb pdb:5DC4|rcsb pdb:5DC9|rcsb pdb:5HU9|rcsb pdb:5MO4|rcsb pdb:5NP2|rcsb pdb:5OAZ|rcsb pdb:6AMV|rcsb pdb:6AMW|rcsb pdb:6BL8|rcsb pdb:6NPE|rcsb pdb:6NPU|rcsb pdb:6NPV|rcsb pdb:6XR6|rcsb pdb:6XR7|rcsb pdb:6XRG|rcsb pdb:7CC2|rcsb pdb:7DT2|reactome:R-HSA-2029482|reactome:R-HSA-428890|reactome:R-HSA-525793|reactome:R-HSA-5663213|reactome:R-HSA-5685938|reactome:R-HSA-5693565|reactome:R-HSA-69231|reactome:R-HSA-8939236|reactome:R-HSA-8940973|reactome:R-HSA-9664422|reactome:R-HSA-983231|dip:DIP-1042N	psi-mi:"MI:0469"(intact)	-	-	figure legend:1 D|comment:The Fus1 peptide was modified with a stearate N-terminal moiety. The Fus1 peptide lacking the stearate N-terminal moiety did not inhibit Abl kinase activity.|inhibition:Stearate-Fus1 peptide - The peptide inhibits Abl activity and inhibition increases as the concentration of peptide is increased.|dataset:Apoptosis - Interactions involving proteins with a function related to apoptosis|dataset:Cancer - Interactions investigated in the context of cancer|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2007/10/30	2014/10/16	rogid:9N2UeTRz21JSb1P1m4iqAz2hz/Y-2	rogid:t7dT+fWrrK2QaWF4U0HQaVgHKUc9606	intact-crc:F602B755315206CE|rigid:9vFp8QSHiBLCzCYIr2DQT6G4UhE	false	-	-	-	-	psi-mi:"MI:0396"(predetermined participant)	psi-mi:"MI:0396"(predetermined participant)
intact:EBI-3946155	uniprotkb:O75896	-	intact:EBI-1052725|uniprotkb:B2R4Y9|ensembl:ENSP00000232496	psi-mi:abl-tide(display_short)|psi-mi:EBI-3946155(display_long)	psi-mi:tusc2_human(display_long)|uniprotkb:PDGFA-associated protein 2(gene name synonym)|uniprotkb:Fusion 1 protein(gene name synonym)|uniprotkb:TUSC2(gene name)|psi-mi:TUSC2(display_short)|uniprotkb:FUS1(gene name synonym)|uniprotkb:LGCC(gene name synonym)|uniprotkb:PDAP2(gene name synonym)|uniprotkb:C3orf11(gene name synonym)	psi-mi:"MI:0424"(protein kinase assay)	Lin et al. (2007)	imex:IM-14938|pubmed:17486070	taxid:-2(chemical synthesis)|taxid:-2("Chemical synthesis (Chemical synthesis)")	taxid:9606(human)|taxid:9606(Homo sapiens)	psi-mi:"MI:0414"(enzymatic reaction)	psi-mi:"MI:0469"(IntAct)	intact:EBI-1550813|imex:IM-14938-2	-	psi-mi:"MI:1060"(spoke expansion)	psi-mi:"MI:0502"(enzyme target)	psi-mi:"MI:0586"(inhibitor)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0499"(unspecified role)	psi-mi:"MI:0327"(peptide)	psi-mi:"MI:0326"(protein)	-	refseq:NP_009206.1|ensembl:ENSG00000114383(gene)|ensembl:ENST00000232496(transcript)|go:"GO:0001779"(natural killer cell differentiation)|go:"GO:0005739"(mitochondrion)|go:"GO:0006909"(phagocytosis)|go:"GO:0006954"(inflammatory response)|go:"GO:0007049"(cell cycle)|go:"GO:0032700"(negative regulation of interleukin-17 production)|go:"GO:0032733"(positive regulation of interleukin-10 production)|go:"GO:0048469"(cell maturation)|go:"GO:0051881"(regulation of mitochondrial membrane potential)|go:"GO:0070945"(neutrophil-mediated killing of gram-negative bacterium)|go:"GO:2000377"(regulation of reactive oxygen species metabolic process)|interpro:IPR029393	psi-mi:"MI:0469"(intact)	-	-	figure legend:1 D|comment:The Fus1 peptide was modified with a stearate N-terminal moiety. The Fus1 peptide lacking the stearate N-terminal moiety did not inhibit Abl kinase activity.|inhibition:Stearate-Fus1 peptide - The peptide inhibits Abl activity and inhibition increases as the concentration of peptide is increased.|dataset:Apoptosis - Interactions involving proteins with a function related to apoptosis|dataset:Cancer - Interactions investigated in the context of cancer|full coverage:Only protein-protein interactions|curation depth:imex curation	taxid:-1(in vitro)|taxid:-1(In vitro)	-	2007/10/30	2014/10/16	rogid:9N2UeTRz21JSb1P1m4iqAz2hz/Y-2	rogid:mNKu48f2Yc8KQdyQ8gQXjfTnD1c9606	intact-crc:F602B755315206CE|rigid:9vFp8QSHiBLCzCYIr2DQT6G4UhE	false	-	sufficient binding region:75-97|lipoconjugated residue:n-n	-	-	psi-mi:"MI:0396"(predetermined participant)	psi-mi:"MI:0396"(predetermined participant)